Vivek Subbiah: Such a delight to have our paper published in a journal with the highest impact factor
Vivek Subbiah shared on LinkedIn:
“2023 Impact factors for all journals are out!!!
CA: A Cancer Journal for Clinicians – American Cancer Society ‘s flagship journal
with an impact factor of 503.1 is the highest. This is from the Cancer Statistics paper that gets cited a lot.
Lancet IF = 98.4 and NEJM IF = 96.2.
Such a delight to have our paper published in a journal with the highest impact factor. Read the OPEN access paper.
The evolving landscape of tissue-agnostic therapies in precision oncology Precision Medicine for the win.”
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.
